AVDL

AVDL

USD

Avadel Pharmaceuticals plc Ordinary Share

$18.780+0.030 (0.160%)

Reaalajas hind

Healthcare
Drug Manufacturers - Specialty & Generic
Iirimaa

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$18.750

Kõrge

$18.780

Madal

$18.680

Maht

1.08M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.8B

Tööstusharu

Drug Manufacturers - Specialty & Generic

Riik

Ireland

Kauplemisstatistika

Keskmine maht

2.43M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $6.38Praegune $18.780Kõrge $19.06

Seotud uudised

Analyst Upgrades

UBS Downgrades Avadel Pharmaceuticals to Neutral, Maintains Price Target to $20

UBS analyst Ashwani Verma downgrades Avadel Pharmaceuticals from Buy to Neutral and maintains the price target from $20 to $20.

Vaata rohkem
UBS Downgrades Avadel Pharmaceuticals to Neutral, Maintains Price Target to $20
Analyst Upgrades

Leerink Partners Downgrades Avadel Pharmaceuticals to Market Perform, Announces $18.5 Price Target

Leerink Partners analyst Marc Goodman downgrades Avadel Pharmaceuticals from Outperform to Market Perform and announces $18.5 price target.

Vaata rohkem
Leerink Partners Downgrades Avadel Pharmaceuticals to Market Perform, Announces $18.5 Price Target
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

Vaata rohkem
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)
PR Newswire

HALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND CONTACT THE LAW FIRM

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Vaata rohkem
HALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND CONTACT THE LAW FIRM
Analyst Upgrades

Jefferies Downgrades Avadel Pharmaceuticals to Hold, Lowers Price Target to $20

Jefferies analyst Andrew Tsai downgrades Avadel Pharmaceuticals from Buy to Hold and lowers the price target from $22 to $20.

Vaata rohkem
Jefferies Downgrades Avadel Pharmaceuticals to Hold, Lowers Price Target to $20
Analyst Upgrades

Needham Downgrades Avadel Pharmaceuticals to Hold

Needham analyst Ami Fadia downgrades Avadel Pharmaceuticals from Buy to Hold.

GlobeNewswire

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement

DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.